Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study

[1]  Z. Hou,et al.  Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges , 2020, International journal of medical sciences.

[2]  M. Cappellini,et al.  Management of age-associated medical complications in patients with β-thalassemia , 2020, Expert review of hematology.

[3]  E. Domingo,et al.  Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. , 2019, Antiviral research.

[4]  S. Alavian,et al.  Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. , 2019, Microbial drug resistance.

[5]  M. Tabrizi Namini,et al.  β-Thalassemia in Iran: Things Everyone Needs to Know About This Disease , 2019, Hemoglobin.

[6]  J. Pawlotsky.  Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures , 2019, Seminars in Liver Disease.

[7]  A. Galli,et al.  Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions , 2019, Viruses.

[8]  F. Ceccherini‐Silberstein,et al.  NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients , 2019, Cells.

[9]  A. Pourfathollah,et al.  Thalassaemia in Iran: Thalassaemia prevention and blood adequacy for thalassaemia treatment , 2018, ISBT Science Series.

[10]  F. Bokharaei-Salim,et al.  Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta‐thalassemia major: Occult HCV infection , 2018, Journal of medical virology.

[11]  M. Imamura,et al.  Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. , 2018, Biochemical and biophysical research communications.

[12]  O. Mahmoud,et al.  Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin , 2018 .

[13]  C. Schuster,et al.  Host-targeting therapies for hepatitis C virus infection: current developments and future applications , 2018, Therapeutic advances in gastroenterology.

[14]  M. Behzadifar,et al.  The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis , 2018, Archives of Virology.

[15]  J. Joy,et al.  The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus , 2018, Virus evolution.

[16]  H. Sima,et al.  Distribution of Hepatitis C Virus Genotypes in Patients with Major β-Thalassemia in Mashhad, Northeast Iran , 2018, Middle East journal of digestive diseases.

[17]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[18]  F. Carrilho,et al.  Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil , 2017, BMC Infectious Diseases.

[19]  Y. Liu,et al.  Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients , 2017, BioMed research international.

[20]  R. Merchant,et al.  Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major. , 2017, Journal of clinical and experimental hepatology.

[21]  A. Luetkemeyer,et al.  Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. , 2017, Topics in antiviral medicine.

[22]  H. Keyvani,et al.  Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy. , 2017, Microbial pathogenesis.

[23]  M. Stanojevic,et al.  Intravenous drug use – an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients , 2017, Archives of medical science : AMS.

[24]  Y. F. Ibrahim,et al.  Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction , 2017, Journal of translational internal medicine.

[25]  S. Taylor-Robinson,et al.  Hepatitis C in Egypt – past, present, and future , 2016, International journal of general medicine.

[26]  V. Soriano,et al.  Hepatitis C virus resistance to the new direct-acting antivirals , 2016, Expert opinion on drug metabolism & toxicology.

[27]  Jean-Michel Pawlotsky,et al.  Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.

[28]  V. Soriano,et al.  Prevention and management of treatment failure to new oral hepatitis C drugs , 2016, Expert opinion on pharmacotherapy.

[29]  J. A. Patino-Galindo,et al.  Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6 , 2016, Antimicrobial Agents and Chemotherapy.

[30]  S. Zeuzem,et al.  Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients , 2015, PloS one.

[31]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[32]  T. Swan,et al.  A path to eradication of hepatitis C in low- and middle-income countries. , 2015, Antiviral research.

[33]  T. Pilot‐Matias,et al.  Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir , 2015, Antimicrobial Agents and Chemotherapy.

[34]  D. Roshani,et al.  Prevalence of Hepatitis C Virus Genotypes in Iranian Patients: A Systematic Review and Meta-Analysis , 2014, Hepatitis monthly.

[35]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[36]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[37]  T. Pilot‐Matias,et al.  P1230 LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/– RIBAVIRIN , 2014 .

[38]  F. Ceccherini‐Silberstein,et al.  Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[39]  C. Flexner,et al.  Direct-acting antiviral agents for hepatitis C virus infection. , 2013, Annual review of pharmacology and toxicology.

[40]  Tara L. Kieffer,et al.  Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment , 2012, Journal of Virology.

[41]  Christoph Sarrazin,et al.  Resistance to direct antiviral agents in patients with hepatitis C virus infection. , 2010, Gastroenterology.

[42]  E. Angelucci,et al.  Treatment of hepatitis C in patients with thalassemia , 2008, Haematologica.

[43]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[44]  HCV Testing and Linkage to Care , 2015 .